25 09, 2020

What is Minimal Residual Disease (MRD)?

By | September 25th, 2020|Categories: Early detection, Epigenomics, MRD, Next-generation sequencing|0 Comments

Many of my followers in the cancer space, especially the Hemes folks, will already understand what MRD is and why it’s important. But for those of you who don’t know I thought an explainer might be helpful. I took inspiration from Keiths COVID qPCR explainer and this […]

21 09, 2020

COVID diagnostics from @DNAnudge

By | September 21st, 2020|Categories: Diagnostics Tech, Methods and applications|0 Comments

A recent paper in The Lancet Microbe reports the first data from CovidNudge: DnaNudge’s rapid, lab-free COVID-19 test. The test: DnaNudge uses a SNP-genotyping technology developed by The Technology Partnership in Cambridge and explained in US10093965B2 patent. A sample is introduced into the Nudge cartridge, a disposable, sealed, and integrated lab-on-chip device,  […]

21 09, 2020

@illumina buys @GrailBio for $8 billion

By | September 21st, 2020|Categories: Diagnostics Tech, Early detection, Next-generation sequencing|1 Comment

Wow Illumina just spent $8 billion buying GRAIL; arguably the leader in methylation-based early detection of cancer with their Galleri test (read the press release). Get more info over at the website they’ve put together for the deal at transformingcancerdetection.com, which includes a presentation that also highlights […]

10 09, 2020

@10xGenomics buys @CARTANAbio for in situ GX analysis validation

By | September 10th, 2020|Categories: 10X Genomics, Methods and applications, Next-generation sequencing, Single-cell sequencing|0 Comments

CARTANA in situ sequencing was just bought by 10X Genomics for $41.2 million. They provide a complement to the Visium technology that generates beautiful gene expression maps of tissue sections as seen in Fig 1c of a recent bioRxiv report (see below). The method was […]

4 08, 2020

UK COVID diagnostics from @nanopore and @DNANudge

By | August 4th, 2020|Categories: Diagnostics Tech, Methods and applications, Nanopore sequencing, Next-generation sequencing|0 Comments

The UK biotech sector was in the news yesterday morning with two companies and their COVID tests making headlines: Oxford Nanopore and DNANudge. Both are offering rapid testing for COVID-19 in the NHS and in care homes (where they are desperately needed). There is only […]

30 07, 2020

Happy 6th birthday $1000 genome…

By | July 30th, 2020|Categories: Epigenomics, Next-generation sequencing, Other stuff|0 Comments

When I wrote the post about the $1000 genome’s upcoming 5th birthday last Summer I was hoping the Moore’s Law genome graph would restart it’s downward trajectory. That has not happened according to todays look at their graphic. I’m beginning to wonder how long we’ll […]

23 06, 2020

Brain cancer testing without the invasive biopsy from @decarvalho_lab

By | June 23rd, 2020|Categories: Diagnostics Tech, Early detection, Epigenomics|0 Comments

Brain cancer is difficult to diagnose and stratify without an invasive biopsy. Daniel De Carvalho’s group have used their cfChIP-Seq technology to non-invasively diagnose and classify brain tumours, potentially removing the need for surgical tissue biopsies. The power of the assay comes from its use of […]

18 06, 2020

Tumour-informed sequencing to increase the sensitivity of ctDNA liquid biopsy

By | June 18th, 2020|Categories: ctDNA, Diagnostics Tech, MRD|0 Comments

A new paper from Nitzan Rosenfeld’s group at CRUK-CI (my old stomping ground) reports astounding sensitivity for ctDNA liquid biopsy. In “ctDNA monitoring using patient-specific sequencing and integration of variant reads” Jonathan Wan and his co-authors performed whole exome sequencing on tumour biopsies (and PBMCs) […]

Load More Posts